An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects
There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promisin...
Gespeichert in:
| Veröffentlicht in: | Journal of psychopharmacology (Oxford) 2010-09, Vol.24 (9), p.1375-1380 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1380 |
|---|---|
| container_issue | 9 |
| container_start_page | 1375 |
| container_title | Journal of psychopharmacology (Oxford) |
| container_volume | 24 |
| creator | Paparrigopoulos, T. Tzavellas, E. Karaiskos, D. Malitas, P. Liappas, I. |
| description | There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global functioning was observed in both groups throughout the study, subjects on tiagabine improved significantly more compared to the control subjects (P < 0.001). Furthermore, the relapse rate in the tiagabine group was lower than in the control group (7 vs 14.3%). Tiagabine was well tolerated and only a minority of the participants reported some adverse effects in the beginning of tiagabine treatment. Results from this study suggest that tiagabine is a safe and effective medication for the management of alcohol dependence when given adjunctively to a standard psychotherapy treatment. Further studies are warranted before definite conclusions can be reached. |
| doi_str_mv | 10.1177/0269881109103799 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_755137587</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_0269881109103799</sage_id><sourcerecordid>748999556</sourcerecordid><originalsourceid>FETCH-LOGICAL-c426t-2cfc9fc9f9335de409329083c31f54089220ab660018049b58e9caf696bb503d3</originalsourceid><addsrcrecordid>eNqFkc2LFDEQxYMo7rh69yQBEU-t-e6Ut2XxCxa86MFTk05X1iyZZOx0H-a_N80MKgsiFORQv3r1Ko-Q55y94bzv3zJhwFrOGXAme4AHZMeV4V0vrH5Idlu72_oX5Emtd4xxo4x-TC44SGVEb3fk-1Wm5YCZHmIqC63LOh1pCXSJ7taNMSONmbrky4-S6ISNnDB7fEeXknBuRIrLkbo8UZ9ijt4liiGgX-pT8ii4VPHZ-b0k3z68_3r9qbv58vHz9dVN55UwSyd88LAVSKknVAykAGallzxoxSwIwdxoTDNvmYJRWwTvggEzjprJSV6S1yfdw1x-rliXYR-rx5RcxrLWodeay17b_v-ksgCgtWnky3vkXVnn3M4YOAjLTfPFGsVOlJ9LrTOG4TDHvZuPA2fDls9wP5828uIsvI57nP4MnANpwKsz4Gr7zDC77GP9zQklQGqzCXUnrrpb_Mvdvxb_Aj8Gooc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1928160890</pqid></control><display><type>article</type><title>An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Paparrigopoulos, T. ; Tzavellas, E. ; Karaiskos, D. ; Malitas, P. ; Liappas, I.</creator><creatorcontrib>Paparrigopoulos, T. ; Tzavellas, E. ; Karaiskos, D. ; Malitas, P. ; Liappas, I.</creatorcontrib><description>There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global functioning was observed in both groups throughout the study, subjects on tiagabine improved significantly more compared to the control subjects (P < 0.001). Furthermore, the relapse rate in the tiagabine group was lower than in the control group (7 vs 14.3%). Tiagabine was well tolerated and only a minority of the participants reported some adverse effects in the beginning of tiagabine treatment. Results from this study suggest that tiagabine is a safe and effective medication for the management of alcohol dependence when given adjunctively to a standard psychotherapy treatment. Further studies are warranted before definite conclusions can be reached.</description><identifier>ISSN: 0269-8811</identifier><identifier>EISSN: 1461-7285</identifier><identifier>DOI: 10.1177/0269881109103799</identifier><identifier>PMID: 19346278</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Addictive behaviors ; Adolescent ; Adult ; Adult and adolescent clinical studies ; Aged ; Alcohol ; Alcohol-Induced Disorders, Nervous System - drug therapy ; Alcohol-Related Disorders - drug therapy ; Alcoholics ; Alcoholism ; Alcoholism and acute alcohol poisoning ; Alcohols ; Anticonvulsants ; Anxiety ; Anxiety - drug therapy ; Biological and medical sciences ; Detoxification ; Drinking behavior ; Drug abuse ; Drug dependence ; Female ; GABA Uptake Inhibitors - adverse effects ; GABA Uptake Inhibitors - therapeutic use ; Humans ; Male ; Medical sciences ; Mental depression ; Middle Aged ; Neuropharmacology ; Nipecotic Acids - adverse effects ; Nipecotic Acids - therapeutic use ; Pharmacology. Drug treatments ; Pilot Projects ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology ; Psychopathology. Psychiatry ; Psychotherapy ; Side effects ; Substance Withdrawal Syndrome - drug therapy ; Tiagabine ; Toxicology ; Withdrawal ; Young Adult</subject><ispartof>Journal of psychopharmacology (Oxford), 2010-09, Vol.24 (9), p.1375-1380</ispartof><rights>The Author(s), 2010.</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c426t-2cfc9fc9f9335de409329083c31f54089220ab660018049b58e9caf696bb503d3</citedby><cites>FETCH-LOGICAL-c426t-2cfc9fc9f9335de409329083c31f54089220ab660018049b58e9caf696bb503d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/0269881109103799$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/0269881109103799$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>315,782,786,21826,27931,27932,43628,43629</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24293569$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19346278$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paparrigopoulos, T.</creatorcontrib><creatorcontrib>Tzavellas, E.</creatorcontrib><creatorcontrib>Karaiskos, D.</creatorcontrib><creatorcontrib>Malitas, P.</creatorcontrib><creatorcontrib>Liappas, I.</creatorcontrib><title>An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects</title><title>Journal of psychopharmacology (Oxford)</title><addtitle>J Psychopharmacol</addtitle><description>There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global functioning was observed in both groups throughout the study, subjects on tiagabine improved significantly more compared to the control subjects (P < 0.001). Furthermore, the relapse rate in the tiagabine group was lower than in the control group (7 vs 14.3%). Tiagabine was well tolerated and only a minority of the participants reported some adverse effects in the beginning of tiagabine treatment. Results from this study suggest that tiagabine is a safe and effective medication for the management of alcohol dependence when given adjunctively to a standard psychotherapy treatment. Further studies are warranted before definite conclusions can be reached.</description><subject>Addictive behaviors</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Aged</subject><subject>Alcohol</subject><subject>Alcohol-Induced Disorders, Nervous System - drug therapy</subject><subject>Alcohol-Related Disorders - drug therapy</subject><subject>Alcoholics</subject><subject>Alcoholism</subject><subject>Alcoholism and acute alcohol poisoning</subject><subject>Alcohols</subject><subject>Anticonvulsants</subject><subject>Anxiety</subject><subject>Anxiety - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Detoxification</subject><subject>Drinking behavior</subject><subject>Drug abuse</subject><subject>Drug dependence</subject><subject>Female</subject><subject>GABA Uptake Inhibitors - adverse effects</subject><subject>GABA Uptake Inhibitors - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mental depression</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Nipecotic Acids - adverse effects</subject><subject>Nipecotic Acids - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Pilot Projects</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychotherapy</subject><subject>Side effects</subject><subject>Substance Withdrawal Syndrome - drug therapy</subject><subject>Tiagabine</subject><subject>Toxicology</subject><subject>Withdrawal</subject><subject>Young Adult</subject><issn>0269-8811</issn><issn>1461-7285</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc2LFDEQxYMo7rh69yQBEU-t-e6Ut2XxCxa86MFTk05X1iyZZOx0H-a_N80MKgsiFORQv3r1Ko-Q55y94bzv3zJhwFrOGXAme4AHZMeV4V0vrH5Idlu72_oX5Emtd4xxo4x-TC44SGVEb3fk-1Wm5YCZHmIqC63LOh1pCXSJ7taNMSONmbrky4-S6ISNnDB7fEeXknBuRIrLkbo8UZ9ijt4liiGgX-pT8ii4VPHZ-b0k3z68_3r9qbv58vHz9dVN55UwSyd88LAVSKknVAykAGallzxoxSwIwdxoTDNvmYJRWwTvggEzjprJSV6S1yfdw1x-rliXYR-rx5RcxrLWodeay17b_v-ksgCgtWnky3vkXVnn3M4YOAjLTfPFGsVOlJ9LrTOG4TDHvZuPA2fDls9wP5828uIsvI57nP4MnANpwKsz4Gr7zDC77GP9zQklQGqzCXUnrrpb_Mvdvxb_Aj8Gooc</recordid><startdate>20100901</startdate><enddate>20100901</enddate><creator>Paparrigopoulos, T.</creator><creator>Tzavellas, E.</creator><creator>Karaiskos, D.</creator><creator>Malitas, P.</creator><creator>Liappas, I.</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20100901</creationdate><title>An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects</title><author>Paparrigopoulos, T. ; Tzavellas, E. ; Karaiskos, D. ; Malitas, P. ; Liappas, I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c426t-2cfc9fc9f9335de409329083c31f54089220ab660018049b58e9caf696bb503d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Addictive behaviors</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Aged</topic><topic>Alcohol</topic><topic>Alcohol-Induced Disorders, Nervous System - drug therapy</topic><topic>Alcohol-Related Disorders - drug therapy</topic><topic>Alcoholics</topic><topic>Alcoholism</topic><topic>Alcoholism and acute alcohol poisoning</topic><topic>Alcohols</topic><topic>Anticonvulsants</topic><topic>Anxiety</topic><topic>Anxiety - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Detoxification</topic><topic>Drinking behavior</topic><topic>Drug abuse</topic><topic>Drug dependence</topic><topic>Female</topic><topic>GABA Uptake Inhibitors - adverse effects</topic><topic>GABA Uptake Inhibitors - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mental depression</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Nipecotic Acids - adverse effects</topic><topic>Nipecotic Acids - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Pilot Projects</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychotherapy</topic><topic>Side effects</topic><topic>Substance Withdrawal Syndrome - drug therapy</topic><topic>Tiagabine</topic><topic>Toxicology</topic><topic>Withdrawal</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paparrigopoulos, T.</creatorcontrib><creatorcontrib>Tzavellas, E.</creatorcontrib><creatorcontrib>Karaiskos, D.</creatorcontrib><creatorcontrib>Malitas, P.</creatorcontrib><creatorcontrib>Liappas, I.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of psychopharmacology (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paparrigopoulos, T.</au><au>Tzavellas, E.</au><au>Karaiskos, D.</au><au>Malitas, P.</au><au>Liappas, I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects</atitle><jtitle>Journal of psychopharmacology (Oxford)</jtitle><addtitle>J Psychopharmacol</addtitle><date>2010-09-01</date><risdate>2010</risdate><volume>24</volume><issue>9</issue><spage>1375</spage><epage>1380</epage><pages>1375-1380</pages><issn>0269-8811</issn><eissn>1461-7285</eissn><abstract>There is evidence that GABAergic anticonvulsants can be efficacious in the treatment of alcohol dependence and in the prevention of alcohol relapse because these agents act on the substrate that is involved in alcoholism. Tiagabine, a selective GABA transporter1 reuptake inhibitor, may be a promising candidate for the treatment of alcohol-dependent individuals. In this randomized, open pilot study, we aimed to investigate the efficacy and tolerability of tiagabine as adjunctive treatment of alcohol-dependent individuals (N = 60) during the immediate post-detoxification period and during a 6-month follow-up period following alcohol withdrawal. A control non-medicated group of alcohol-dependent individuals (N = 60) was used for comparisons in terms of anxiety and depressive symptoms, craving and drinking outcome. Although a steady improvement in terms of psychopathology, craving and global functioning was observed in both groups throughout the study, subjects on tiagabine improved significantly more compared to the control subjects (P < 0.001). Furthermore, the relapse rate in the tiagabine group was lower than in the control group (7 vs 14.3%). Tiagabine was well tolerated and only a minority of the participants reported some adverse effects in the beginning of tiagabine treatment. Results from this study suggest that tiagabine is a safe and effective medication for the management of alcohol dependence when given adjunctively to a standard psychotherapy treatment. Further studies are warranted before definite conclusions can be reached.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>19346278</pmid><doi>10.1177/0269881109103799</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-8811 |
| ispartof | Journal of psychopharmacology (Oxford), 2010-09, Vol.24 (9), p.1375-1380 |
| issn | 0269-8811 1461-7285 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_755137587 |
| source | Access via SAGE; MEDLINE |
| subjects | Addictive behaviors Adolescent Adult Adult and adolescent clinical studies Aged Alcohol Alcohol-Induced Disorders, Nervous System - drug therapy Alcohol-Related Disorders - drug therapy Alcoholics Alcoholism Alcoholism and acute alcohol poisoning Alcohols Anticonvulsants Anxiety Anxiety - drug therapy Biological and medical sciences Detoxification Drinking behavior Drug abuse Drug dependence Female GABA Uptake Inhibitors - adverse effects GABA Uptake Inhibitors - therapeutic use Humans Male Medical sciences Mental depression Middle Aged Neuropharmacology Nipecotic Acids - adverse effects Nipecotic Acids - therapeutic use Pharmacology. Drug treatments Pilot Projects Psychology. Psychoanalysis. Psychiatry Psychopathology Psychopathology. Psychiatry Psychotherapy Side effects Substance Withdrawal Syndrome - drug therapy Tiagabine Toxicology Withdrawal Young Adult |
| title | An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T07%3A04%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20open%20pilot%20study%20of%20tiagabine%20in%20alcohol%20dependence:%20tolerability%20and%20clinical%20effects&rft.jtitle=Journal%20of%20psychopharmacology%20(Oxford)&rft.au=Paparrigopoulos,%20T.&rft.date=2010-09-01&rft.volume=24&rft.issue=9&rft.spage=1375&rft.epage=1380&rft.pages=1375-1380&rft.issn=0269-8811&rft.eissn=1461-7285&rft_id=info:doi/10.1177/0269881109103799&rft_dat=%3Cproquest_cross%3E748999556%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1928160890&rft_id=info:pmid/19346278&rft_sage_id=10.1177_0269881109103799&rfr_iscdi=true |